- Home
- CCEL vs CALC Comparison
CCEL vs CALC Comparison
Compare CCEL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- CALC
- Stock Information
- Founded
- CCEL 1989
- CALC 2011
- Country
- CCEL United States
- CALC United States
- Employees
- CCEL N/A
- CALC N/A
- Industry
- CCEL Managed Health Care
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- CALC Health Care
- Exchange
- CCEL Nasdaq
- CALC Nasdaq
- Market Cap
- CCEL 39.9M
- CALC 22.9M
- IPO Year
- CCEL 1997
- CALC N/A
- Fundamental
- Price
- CCEL $4.99
- CALC $1.64
- Analyst Decision
- CCEL Strong Buy
- CALC Strong Buy
- Analyst Count
- CCEL 1
- CALC 3
- Target Price
- CCEL $8.50
- CALC $16.33
- AVG Volume (30 Days)
- CCEL 13.3K
- CALC 28.9K
- Earning Date
- CCEL 07-14-2025
- CALC 08-11-2025
- Dividend Yield
- CCEL 19.76%
- CALC N/A
- EPS Growth
- CCEL N/A
- CALC N/A
- EPS
- CCEL 0.01
- CALC N/A
- Revenue
- CCEL $32,102,750.00
- CALC N/A
- Revenue This Year
- CCEL $2.49
- CALC N/A
- Revenue Next Year
- CCEL $0.95
- CALC N/A
- P/E Ratio
- CCEL $560.42
- CALC N/A
- Revenue Growth
- CCEL 2.33
- CALC N/A
- 52 Week Low
- CCEL $4.75
- CALC $1.42
- 52 Week High
- CCEL $9.43
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- CCEL 45.67
- CALC 49.89
- Support Level
- CCEL $4.87
- CALC $1.59
- Resistance Level
- CCEL $6.35
- CALC $1.69
- Average True Range (ATR)
- CCEL 0.27
- CALC 0.15
- MACD
- CCEL -0.02
- CALC 0.01
- Stochastic Oscillator
- CCEL 8.11
- CALC 52.26
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.